STOCK TITAN

KALA BIO (KALA) director files Form 3 disclosing no beneficial share ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

KALA BIO director reports no stock ownership in initial filing

Director Colman Yonatan C. filed an initial ownership report with KALA BIO, Inc. stating that no securities are beneficially owned. The form also notes that a Power of Attorney authorizes Avraham Minkowitz to sign and submit the filing on the director’s behalf.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Colman Yonatan C.

(Last) (First) (Middle)
1167 MASSACHUSETTS AVENUE

(Street)
ARLINGTON MA 02476

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/30/2026
3. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
The Power of Attorney, executed by the Reporting Person, authorizing Avraham Minkowitz to sign and file this Form 3 on the Reporting Person's behalf is attached hereto as Exhibit 24.
No securities are beneficially owned.
/s/ Avraham Minkowitz, Attorney-in-Fact 02/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the KALA Form 3 filed by Colman Yonatan C. show?

The Form 3 states that director Colman Yonatan C. currently has no beneficial ownership of KALA BIO, Inc. securities. It is an initial ownership report required when someone becomes a director, officer, or 10% shareholder of a public company.

Does the KALA director on this Form 3 own any KALA BIO shares?

According to the filing, no securities are beneficially owned by the reporting person. Both the non-derivative and derivative tables show no holdings, and the remarks section explicitly confirms that no securities are beneficially owned at this time.

Who signed the KALA (KALA) Form 3 and why?

The Form 3 was signed by Avraham Minkowitz as Attorney-in-Fact for director Colman Yonatan C. A Power of Attorney attached as Exhibit 24 authorizes Minkowitz to sign and file ownership reports on the director’s behalf with the SEC.

What is the relationship of the reporting person to KALA BIO on this Form 3?

The reporting person, Colman Yonatan C., is identified as a director of KALA BIO, Inc. The filing indicates he is not a 10% owner and does not serve as an officer, with only the director box checked among the relationship options.

Why was this KALA BIO Form 3 required on January 30, 2026?

The Form 3 is required when an individual first becomes subject to Section 16 reporting, such as becoming a director. The filing lists January 30, 2026, as the date of the event that triggered the need for this initial ownership statement.
Kala Pharmaceuticals Inc

NASDAQ:KALA

KALA Rankings

KALA Latest News

KALA Latest SEC Filings

KALA Stock Data

12.25M
8.10M
1.75%
51.86%
5.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ARLINGTON